LLY
911.65
+0.96%↑
JNJ
235.8
+0.14%↑
ABBV
205.01
+0.38%↑
NVS
147.58
+1.16%↑
AZN
184.25
+0.48%↑
LLY
911.65
+0.96%↑
JNJ
235.8
+0.14%↑
ABBV
205.01
+0.38%↑
NVS
147.58
+1.16%↑
AZN
184.25
+0.48%↑
LLY
911.65
+0.96%↑
JNJ
235.8
+0.14%↑
ABBV
205.01
+0.38%↑
NVS
147.58
+1.16%↑
AZN
184.25
+0.48%↑
LLY
911.65
+0.96%↑
JNJ
235.8
+0.14%↑
ABBV
205.01
+0.38%↑
NVS
147.58
+1.16%↑
AZN
184.25
+0.48%↑
LLY
911.65
+0.96%↑
JNJ
235.8
+0.14%↑
ABBV
205.01
+0.38%↑
NVS
147.58
+1.16%↑
AZN
184.25
+0.48%↑
24h
Current
Min
10.44
Max
11.16
Income | -3.3M -4.7M |
|---|---|
Sales | -1.1M 3.1M |
EPS | -1.46 |
Profit margin | -148.854 |
Employees | 50 |
EBITDA | -2.7M -3.8M |
Market Cap | 1.9M 40M |
|---|---|
Previous open | 8.12 |
Previous close | 10.71 |
By Trading Central
Confidence
Bearish Evidence
0.4084 / 0.4998 Support & Resistance
Past performance is not a reliable indicator of future results.
23 Mar 2026, 23:47 UTC
Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update
DJ
Read
23 Mar 2026, 22:55 UTC
Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion
DJ
Read
23 Mar 2026, 21:51 UTC
Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update
DJ
Read
23 Mar 2026, 23:59 UTC
Global Equities Roundup: Market Talk
DJ
Read
23 Mar 2026, 23:59 UTC
Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk
DJ
Read
23 Mar 2026, 23:50 UTC
Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk
DJ
Read
23 Mar 2026, 23:37 UTC
Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk
DJ
Read
23 Mar 2026, 22:42 UTC
Global Equities Roundup: Market Talk
DJ
Read
23 Mar 2026, 22:42 UTC
Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk
DJ
Read
23 Mar 2026, 22:40 UTC
Gilead Sciences to Buy Ouro Medicines for Up to $2.18B
DJ
Read
23 Mar 2026, 22:23 UTC
Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk
DJ
Read
23 Mar 2026, 22:22 UTC
Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease
DJ
Read
23 Mar 2026, 22:21 UTC
Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales
DJ
Read
23 Mar 2026, 22:21 UTC
Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China
DJ
Read
23 Mar 2026, 22:20 UTC
Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD
DJ
Read
23 Mar 2026, 22:20 UTC
Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD
DJ
Read
23 Mar 2026, 22:19 UTC
Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders
DJ
Read
23 Mar 2026, 22:19 UTC
Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets
DJ
Read
23 Mar 2026, 22:18 UTC
Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD
DJ
Read
23 Mar 2026, 22:15 UTC
Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD
DJ
Read
23 Mar 2026, 22:08 UTC
Ebos Needs to Reset Its Gearing Targets -- Market Talk
DJ
Read
23 Mar 2026, 21:42 UTC
Global Forex and Fixed Income Roundup: Market Talk
DJ
Read
23 Mar 2026, 21:42 UTC
RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk
DJ
Read
23 Mar 2026, 21:32 UTC
WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK
DJ
Read
23 Mar 2026, 21:32 UTC
WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK
DJ
Read
23 Mar 2026, 21:32 UTC
WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK
DJ
Read
23 Mar 2026, 21:10 UTC
Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com
DJ
Read
23 Mar 2026, 20:50 UTC
Tech, Media & Telecom Roundup: Market Talk
DJ
Read
23 Mar 2026, 20:50 UTC
Health Care Roundup: Market Talk
DJ
Read
23 Mar 2026, 20:50 UTC
Basic Materials Roundup: Market Talk
DJ
Read
Price change
By TipRanks
Neutral
1 ratings
0
Buy
1
Hold
0
Sell
Based on 1 analysts giving stock ratings to Ekso Bionics Holdings - Dist in the past 3 months.
By Trading Central
Short Term
Bearish Evidence
Recent bearish events outweigh bullish events.
Intermediate Term
Strong Bullish Evidence
Recent bullish events outweigh bearish events.
Long Term
No Evidence
There are no events.
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$